New Product Or Brand Launch
Expected: FY27 ramp-upHIGH confidence
What: Poviztra Launch: Launched Dec 2025
“This partnership not only gives us first-mover advantage, but also allows us to bring original innovative product to Indian patients.”
Emcure Pharmaceuticals Ltd: Why Is It Outperforming Nifty 500?
ActiveAverage12w Streak
In , Emcure Pharmaceuticals Ltd (Pharma - Formulators) is outperforming Nifty 500 with +9.8% relative strength. Fundamentals: Average. On a 12-week streak.
Emcure Pharmaceuticals Ltd Key Facts
- PE Ratio
- 32.9x
- Price/Book
- 6.06x
- Market Cap
- ₹31,150 Cr
- PAT Growth YoY
- +24%
- Revenue Growth YoY
- +17%
- OPM
- 19.0%
- RS vs Nifty 500
- +9.8%
Strong Opportunity
What's Happening
💎PE falling while earnings hold — value emerging
💰Trading 30% below estimated fair value
Earnings Acceleration Triggers
1. New Product Or Brand Launch
FY27 ramp-upHIGH
2. Geographical Expansion
OngoingHIGH
3. Regulatory Approval Or License Win
Next 24 monthsMEDIUM
Key Risks
1. One-time impact of INR 38 crores due to Labour Code changes
MEDIUM2. Potential for generic competition in the semaglutide market within 1-2 months
MEDIUM3. Currency volatility impact on international revenue and dollar-denominated impor
LOWSector-Specific Signals
Domestic Revenue Growth15.4%+15.4%
International Revenue Growth24.5%+24.5%
Chronic vs Acute Mix50:50Improving
Gross Margin59.3%-80 bps
Key Numbers
PAT Growth YoY
+24%
Stable
Revenue YoY
+17%
Stable
Operating Margin
19.0%
0 bps YoY
PE Ratio
32.9
PEG Ratio
4.10
EV/EBITDA
16.4
Current Price
₹1,643
Dividend Yield
0.18%
Fundamental Score
56/100
Average
3Y PAT CAGR
+19%
Market Cap
31.1K Cr
Valuation
Undervalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
Why Are Emcure Pharmaceuticals Ltd's Earnings Accelerating?
Based on Q3 FY26 earnings • Updated Apr 18, 2026
Geographical Expansion
Expected: OngoingHIGH confidence
What: Europe Revenue Growth: 29.6%
“Europe is seeing strong traction with very strong growth of 29.6% in the quarter, led by ramp-up of base business.”
Regulatory Approval Or License Win
Expected: Next 24 monthsMEDIUM confidence
What: Lenacapavir License: API validation complete
“We have completed our API validation batches at our U.S. FDA approved facility and in terms of formulation... status where we've already entered our plans.”
Operating Leverage Inflection
Expected: FY26MEDIUM confidence
What: EBITDA Margin: 19.5%
Impact: 110 bps expansion
“EBITDA margin stood at 19.5%... supported by operating leverage and productivity gains, which was partly offset by Sanofi OAD addition.”
Value Added Product Mix Shift
Expected: OngoingMEDIUM confidence
What: Chronic Revenue Share: 50%
“So right now, if you look at it, our chronic is now closer to about 50-50 chronic and acute for us.”
Revenue growth of 20.4% YoY
HIGH confidence
What: Revenue growth of 20.4% YoY
“The quarter saw strong performance across all international businesses along all verticals, which helped us to deliver 24.5% by the way of growth.”
What Are the Key Risks for Emcure Pharmaceuticals Ltd?
Earnings deceleration risks from management commentary
One-time impact of INR 38 crores due to Labour Code changes
MEDIUMTrigger: Regulatory changes in labor laws requiring additional provisioning.
Impact: PAT impact: INR 38 crores
Management view: Treated as an exceptional item; one-time impact.
Monitor: labor
Potential for generic competition in the semaglutide market within 1-2 months
MEDIUMTrigger: Patent expiries and domestic competitors launching generic versions.
Management view: Focusing on innovator brand recall and cardiac comorbidity data to differentiate.
Monitor: regulatory
Currency volatility impact on international revenue and dollar-denominated impor
LOWTrigger: Fluctuations in global currencies against the INR.
Impact: PAT impact: Net-neutral
Management view: Natural hedge through imports in dollar terms.
Monitor: fx
What Is Emcure Pharmaceuticals Ltd's Management Saying?
Key quotes from recent conference calls
“So I think what we have guided for is we expect this year the base margins to improve by about 150 basis points. [Previous Base Margin Improvement guidance]”
“And we became the only company to launch the innovator drug in the game-changing semaglutide category. [Initiative: Novo Nordisk Partnership (Poviztra)]”
“During the quarter, we also took an exceptional expense of INR 38 crores related to Labour Code changes. [Risk (labor): MEDIUM]”
“Plus there would be a generic competition on the semaglutide, which will come in maybe over the next 1 or 2 months. [Risk (regulatory): MEDIUM]”
What Did Emcure Pharmaceuticals Ltd Report This Quarter?
Headline numbers from the latest earnings call
Revenue
INR 2,363 crores
YoY +20.4%QoQ +4.1%
Why: Growth was driven by strong performance in international markets, particularly Europe, and domestic chronic therapies.
International markets grew 24.5% YoY, outpacing domestic growth.
EBITDA
INR 460 crores
YoY +27.2%Margin 19.5%
Why: Margin expansion was supported by operating leverage and productivity gains, partially offset by the Sanofi OAD portfolio addition.
Margins improved by 110 basis points YoY despite the dilutive impact of in-licensed portfolios.
PAT
INR 231 crores
YoY +48%QoQ -7.9%
Why: PAT growth was strong YoY but impacted by a one-time INR 38 crore exceptional expense related to Labour Code changes.
Adjusted for the labor code provision, PAT growth would have been significantly higher.
Other Highlights
• Net debt increased to INR 1,203 crores due to Zuventus minority stake payout.
• Europe revenue grew 29.6% YoY to INR 464 crores.
• Emerging markets grew 30.7% YoY reaching INR 477 crores.
What Sector Metrics Matter for Emcure Pharmaceuticals Ltd?
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
Domestic Revenue Growth
15.4%
YoY +15.4%
Why: Led by chronic therapies in Cardio-Diabeto, CNS, and oncology.
International Revenue Growth
24.5%
YoY +24.5%
Why: Strong performance in Europe (29.6%) and Emerging Markets (30.7%).
Chronic vs Acute Mix
50:50
YoY Improving
Why: Strategic focus on increasing chronic share through in-licensing and R&D.
Gross Margin
59.3%
YoY -80 bpsQoQ -150 bps
Why: Dilution from Sanofi OAD portfolio and higher international sales mix.
Net Debt
INR 1,203 Cr
QoQ +INR 366 Cr
Why: Payout for Zuventus minority stake purchase.
MR Productivity (PCPM)
7
YoY +15%
Why: Higher productivity in chronic and Women's Health segments.
R&D as % of Sales
Not Given
Why: Maintained in traditional region as a percent of top line.
Amphotericin B European Presence
23 countries
Why: Approvals received; launches rolling out across Western Europe.
What Is Emcure Pharmaceuticals Ltd's Management Guidance?
Forward-looking targets from management for Next 5 years
Revenue Growth Target
13%
OPM Guidance
300–400%
Capex Plan
₹400 Cr
Revenue Outlook
13% to 15%
Margin Outlook
300 to 400 basis point improvement
Capex Plan
INR 300 to 400 crores
Gross block expansion
Management Tone: BULLISH
Guidance Changes
LOWERED
Net Debt: Debt-free by FY26 → Net debt at zero level by December 2028
How Fast Is Emcure Pharmaceuticals Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +17% | +15% | Stable |
| PAT (Net Profit) | +24% | +19% | Stable |
| OPM | 19.0% | 0 bps | Expanding |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 18, 2026.
Other Top Pharma - Formulators Stocks Beating Nifty 500
Frequently Asked Questions: Emcure Pharmaceuticals Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were Emcure Pharmaceuticals Ltd's latest quarterly results?
Emcure Pharmaceuticals Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +23.9% (stable)
- Revenue Growth YoY: +16.7%
- Operating Margin: 19.0% (expanding)
Is Emcure Pharmaceuticals Ltd's profit growing or declining?
Emcure Pharmaceuticals Ltd's profit is growing with an stable trend.
- PAT Growth YoY: +23.9% (latest quarter)
- PAT Growth QoQ: +5.6% (sequential)
- 3-Year PAT CAGR: +18.8%
- Trend: Stable — consistent growth pattern
What is Emcure Pharmaceuticals Ltd's revenue growth trend?
Emcure Pharmaceuticals Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +16.7%
- Revenue Growth QoQ: +4.5% (sequential)
- 3-Year Revenue CAGR: +15.4%
How is Emcure Pharmaceuticals Ltd's operating margin trending?
Emcure Pharmaceuticals Ltd's operating margin is expanding.
- Current OPM: 19.0%
- OPM Change YoY: 0.0% basis points
- OPM Change QoQ: -2.0% basis points
What is Emcure Pharmaceuticals Ltd's 3-year profit and revenue CAGR?
Emcure Pharmaceuticals Ltd's long-term compounding rates
- 3-Year Profit CAGR: +18.8%
- 3-Year Revenue CAGR: +15.4%
Is Emcure Pharmaceuticals Ltd's growth accelerating or decelerating?
Emcure Pharmaceuticals Ltd's earnings growth is stable with mixed signals on a sequential basis.
- YoY Acceleration: -24.2% bps
- Sequential Acceleration: +13.6% bps
What is Emcure Pharmaceuticals Ltd's trailing twelve month (TTM) performance?
Emcure Pharmaceuticals Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹941 Cr
- TTM PAT Growth: +32.9% YoY
- TTM Revenue: ₹9,000 Cr
- TTM Revenue Growth: +16.6% YoY
- TTM Operating Margin: 20.2%
Is Emcure Pharmaceuticals Ltd overvalued or undervalued?
Emcure Pharmaceuticals Ltd appears undervalued based on our fair value analysis.
- Valuation Signal: Undervalued
- Current PE: 32.9x
- Price-to-Book: 6.3x
What is Emcure Pharmaceuticals Ltd's current PE ratio?
Emcure Pharmaceuticals Ltd's current PE ratio is 32.9x.
- Current PE: 32.9x
- Market Cap: 31.1K Cr
- Dividend Yield: 0.18%
How does Emcure Pharmaceuticals Ltd's valuation compare to its history?
Emcure Pharmaceuticals Ltd's current PE is 32.9x.
- Current PE: 32.9x
- Valuation Assessment: Undervalued
What is Emcure Pharmaceuticals Ltd's price-to-book ratio?
Emcure Pharmaceuticals Ltd's price-to-book ratio is 6.3x.
- Price-to-Book (P/B): 6.3x
- Book Value per Share: ₹261
- Current Price: ₹1643
Is Emcure Pharmaceuticals Ltd a fundamentally strong company?
Emcure Pharmaceuticals Ltd is rated Average with a fundamental score of 55.71/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +16.7% (10% weight)
- PAT Growth YoY: +23.9% (10% weight)
- PAT Growth QoQ: +5.6% (10% weight)
- Margins expanding (10% weight)
- PEG Ratio: 4.1x vs sector median (15% weight)
- EV/EBITDA: 16.4x vs sector median (15% weight)
Is Emcure Pharmaceuticals Ltd debt free?
Emcure Pharmaceuticals Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹2,000 Cr
What is Emcure Pharmaceuticals Ltd's return on equity (ROE) and ROCE?
Emcure Pharmaceuticals Ltd's return ratios over recent years
- FY2024: ROCE 19.0%
- FY2025: ROCE 21.0%
- FY2026: ROCE 24.0%
Is Emcure Pharmaceuticals Ltd's cash flow positive?
Emcure Pharmaceuticals Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹944 Cr
- Free Cash Flow (FCF): ₹-249 Cr
- CFO/PAT Ratio: 100% (strong cash conversion)
What is Emcure Pharmaceuticals Ltd's dividend yield?
Emcure Pharmaceuticals Ltd's current dividend yield is 0.18%.
- Dividend Yield: 0.18%
- Current Price: ₹1643
Who holds Emcure Pharmaceuticals Ltd shares — promoters, FII, DII?
Emcure Pharmaceuticals Ltd's shareholding pattern (Mar 2026)
- Promoters: 77.9%
- FII (Foreign): 3.4%
- DII (Domestic): 6.1%
- Public: 12.7%
Is promoter holding increasing or decreasing in Emcure Pharmaceuticals Ltd?
Emcure Pharmaceuticals Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 77.9% (Mar 2026)
- Previous Quarter: 77.9% (Dec 2025)
- Change: 0.00% (stable)
How long has Emcure Pharmaceuticals Ltd been outperforming Nifty 500?
Emcure Pharmaceuticals Ltd has been outperforming Nifty 500 for 12 consecutive weeks, indicating strong sustained outperformance.
Is Emcure Pharmaceuticals Ltd a new momentum entry or an established outperformer?
Emcure Pharmaceuticals Ltd is an established outperformer with 12 weeks of consecutive Nifty 500 outperformance.
What are the growth catalysts for Emcure Pharmaceuticals Ltd?
Emcure Pharmaceuticals Ltd has 6 key growth catalysts identified from recent earnings analysis
- New Product Or Brand Launch — Exclusive distribution of Novo Nordisk's semaglutide brand in India.
- Geographical Expansion — Ramp-up of Amphotericin B and Manx portfolio integration.
- Regulatory Approval Or License Win — Revolutionary HIV treatment with high market potential.
- Operating Leverage Inflection — Productivity gains and fixed cost absorption as revenue scales.
What are the key risks in Emcure Pharmaceuticals Ltd?
Emcure Pharmaceuticals Ltd has 3 key risks worth monitoring
- [MEDIUM] One-time impact of INR 38 crores due to Labour Code changes — Regulatory changes in labor laws requiring additional provisioning.
- [MEDIUM] Potential for generic competition in the semaglutide market within 1-2 months — Patent expiries and domestic competitors launching generic versions.
- [LOW] Currency volatility impact on international revenue and dollar-denominated impor — Fluctuations in global currencies against the INR.
What did Emcure Pharmaceuticals Ltd's management say in the latest earnings call?
In Q3 FY26, Emcure Pharmaceuticals Ltd's management highlighted
- "So I think what we have guided for is we expect this year the base margins to improve by about 150 basis points. [Previous Base Margin Improvement gu..."
- "And we became the only company to launch the innovator drug in the game-changing semaglutide category. [Initiative: Novo Nordisk Partnership (Poviztr..."
- "During the quarter, we also took an exceptional expense of INR 38 crores related to Labour Code changes. [Risk (labor): MEDIUM]"
What is Emcure Pharmaceuticals Ltd's management guidance for growth?
Emcure Pharmaceuticals Ltd's management has provided the following forward guidance for Next 5 years
- Revenue growth target: 13%
- OPM guidance: 300–400%
- Capex plan: ₹400 Cr for Gross block expansion
- Management tone: bullish
- Milestone: [LOWERED] Net Debt: Debt-free by FY26 → Net debt at zero level by December 2028
What sector-specific metrics matter most for Emcure Pharmaceuticals Ltd?
Emcure Pharmaceuticals Ltd's most important sub-sector-specific KPIs from the latest concall
- Domestic Revenue Growth: 15.4% (YoY +15.4%) — Led by chronic therapies in Cardio-Diabeto, CNS, and oncology.
- International Revenue Growth: 24.5% (YoY +24.5%) — Strong performance in Europe (29.6%) and Emerging Markets (30.7%).
- Chronic vs Acute Mix: 50:50 (YoY Improving) — Strategic focus on increasing chronic share through in-licensing and R&D.
- Gross Margin: 59.3% (YoY -80 bps) (QoQ -150 bps) — Dilution from Sanofi OAD portfolio and higher international sales mix.
- Net Debt: INR 1,203 Cr (QoQ +INR 366 Cr) — Payout for Zuventus minority stake purchase.
- MR Productivity (PCPM): 7 (YoY +15%) — Higher productivity in chronic and Women's Health segments.
Is Emcure Pharmaceuticals Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Emcure Pharmaceuticals Ltd may be worth studying
- Earnings growing at +23.9% YoY
- Operating margins are expanding — OPM at 19.0%
- Valuation: appears undervalued
- Cash flow is positive — CFO ₹944 Cr
What is the investment thesis for Emcure Pharmaceuticals Ltd?
Emcure Pharmaceuticals Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +16.7% YoY
- Margins expanding
- Appears undervalued
- Growth catalyst: New Product Or Brand Launch
Risk Factors (Bear Case)
- Key risk: One-time impact of INR 38 crores due to Labour Code changes
What is the future outlook for Emcure Pharmaceuticals Ltd?
Emcure Pharmaceuticals Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: stable
- Margin Trend: expanding
- Valuation: Undervalued
- Key Catalyst: New Product Or Brand Launch
- Key Risk: One-time impact of INR 38 crores due to Labour Code changes
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.